Observational analysis highlights the potential of senotherapeutics and therapy-induced senescence in cancer, suggesting new strategies for treatment.
Key Points
Targeting senescence may enhance cancer therapy effectiveness, offering a dual approach to manage tumor progression and treatment resistance.
Ongoing clinical trials are exploring the role of senotherapeutics alongside senescence-inducing therapies in various cancer types.
Therapy-induced senescence can influence cancer outcomes, raising the importance of understanding its effects in oncology treatments.
Research indicates a strong connection between cellular senescence and aging-related cancer progression, with implications for new therapeutic avenues.